A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

NCT01950364 ↗

Phase 1 Completed 20 enrolled Millennium Pharmaceuticals, Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label trial to estimate the concentrations of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma (HL) or relapsed/refractory systemic anaplastic large cell lymphoma (sALCL) participants treated with either brentuximab vedotin or brentuximab vedotin + rifampicin.

Timeline

Start: 2013-11
Primary completion: 2014-10
Completion: 2015-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brentuximab Vedotin	Monoclonal antibody	1.8 mg/kg	—
Subject	Rifampin	Small molecule	600 mg	Oral

A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Summary

Timeline

Drugs

Indications